Dendritic cells in the tumor microenvironment: prognostic and theranostic impact
Authors:
- 1 April 2020
- journal article
- review article
- Published by Elsevier in Seminars in Immunology
- Vol. 48, 101410
Abstract
No abstract availableKeywords
Funding Information
- Inserm
- Sorbonne Université
- Université de Paris
- CARPEM
- Inca
This publication has 140 references indexed in Scilit:
- IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine ResponsesImmunity, 2013
- Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic CellsImmunity, 2012
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cellsJournal of Experimental Medicine, 2010
- Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cellsJournal of Experimental Medicine, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensJournal of Experimental Medicine, 2010
- Blood-derived dermal langerin+ dendritic cells survey the skin in the steady stateJournal of Experimental Medicine, 2007
- Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligandJournal of Experimental Medicine, 2007